**Description of Additional Supplementary Data Files** 

**Supplementary Data 1** 

Description: Methylation array samples used for classifier generation or reasons for exclusion

**Supplementary Data 2** 

**Description:** Clinical characteristics and T7-MBD-Seq metrics of 79 NCC cfDNA samples used for building the classifiers. Sequencing details for the enriched fraction (blue) and non-enriched fraction

(green).

**Supplementary Data 3** 

**Description:** Clinical characteristics and T7-MBD-Seq metrics of cfDNA from 143 patients and 27 NCCs. Sequencing details for the enriched fractions (blue) and non-enriched fractions (green).

**Supplementary Data 4** 

Description: CUPiD predictions for the independent test cohort, mean values across the 100 sub-

classifiers.

**Supplementary Data 5** 

Description: Clinical and pathological characteristics of CUP cohort, tumour type enriched alterations

(TTAEs) and CUPiD Predictions.

**Supplementary Data 6** 

Description: Sequencing statistics for cfDNA and gDNA targeted mutation sequencing for the CUP

cohort.

**Supplementary Data 7** 

Description: List of relevant mutations found from cfDNA in the 40 patients with CUP with successful

mutation profiling (\*indicates nomenclature for Stop codon).

**Supplementary Data 8** 

**Description:** Clinical characteristics and T7-MBD-Seq metrics from cfDNA samples of 41 patients with

CUP. Sequencing details for the enriched fractions (blue) and non-enriched fractions (green).

**Supplementary Data 9** 

**Description:** CUPiD Predictions in the CUP cohort